Crucell and DSM Announce PER.C6® Licensing Agreement with IQ Corporation for Production of Monoclonal Antibodies against Anthrax
20-Oct-2005 -
Crucell N.V. and allied contract manufacturer DSM Biologics announced that they have signed a PER.C6® research license agreement with Dutch biotechnology company IQ Corporation. This license agreement allows IQ to evaluate and use the PER.C6® cell line for production of its
monoclonal antibody ...
anthrax
biotechnology
cell lines
+2